I agree that licensing is the logical way for Race to commercialize Bisantrene.
Bisantrene has such a diverse opportunity across many cancer types, it needs an owner that can ensure all its benefits make it to market to assist cancer patients. i.e. it would be a shame to see one Big Pharma buy the lot and only invest in their area of cancer expertise, which may cut out other opportunities. Race is well positioned to prosecute all the advantages of Bisantrene.
If they decide to partner up to accelerate the Bisantrene program, well and good.
Good luck to us.
RAC Price at posting:
$1.02 Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)